Kyle W. Sloop

7.3k total citations · 4 hit papers
89 papers, 5.1k citations indexed

About

Kyle W. Sloop is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Kyle W. Sloop has authored 89 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Endocrinology, Diabetes and Metabolism, 51 papers in Molecular Biology and 31 papers in Surgery. Recurrent topics in Kyle W. Sloop's work include Diabetes Treatment and Management (47 papers), Pancreatic function and diabetes (30 papers) and Receptor Mechanisms and Signaling (26 papers). Kyle W. Sloop is often cited by papers focused on Diabetes Treatment and Management (47 papers), Pancreatic function and diabetes (30 papers) and Receptor Mechanisms and Signaling (26 papers). Kyle W. Sloop collaborates with scholars based in United States, Canada and United Kingdom. Kyle W. Sloop's co-authors include Francis S. Willard, Aaron D. Showalter, Matthew P. Coghlan, Ricardo J. Samms, Simon J. Rhodes, Lawrence J. Slieker, David A. D’Alessio, Tamer Coşkun, Daniel A. Briere and Shweta Urva and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Kyle W. Sloop

87 papers receiving 5.0k citations

Hit Papers

LY3298176, a novel dual GIP and GLP-1 receptor agonist fo... 2018 2026 2020 2023 2018 2020 2020 2022 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
    2018 603 citations Tamer Coşkun, Kyle W. Sloop et al. Molecular Metabolism profile →
  2. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
    2020 314 citations Francis S. Willard, Jonathan D. Douros et al. JCI Insight profile →
  3. How May GIP Enhance the Therapeutic Efficacy of GLP-1?
    2020 276 citations Ricardo J. Samms, Matthew P. Coghlan et al. profile →
  4. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
    2022 180 citations Tamer Coşkun, Shweta Urva et al. Cell Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kyle W. Sloop United States 40 2.7k 2.4k 1.3k 1.2k 721 89 5.1k
Tamer Coşkun United States 32 1.7k 0.7× 2.7k 1.1× 997 0.8× 1.6k 1.3× 507 0.7× 98 5.5k
Lotte Bjerre Knudsen Denmark 50 7.1k 2.6× 4.4k 1.8× 3.6k 2.9× 1.5k 1.3× 1.8k 2.5× 105 10.5k
Krister Bokvist Sweden 43 2.0k 0.8× 3.2k 1.3× 3.4k 2.7× 653 0.5× 1.0k 1.4× 82 5.9k
Bernard Portha France 48 2.9k 1.1× 2.3k 1.0× 3.7k 2.9× 1.6k 1.3× 285 0.4× 191 7.1k
Christopher H.S. McIntosh Canada 50 5.3k 2.0× 2.9k 1.2× 3.5k 2.8× 694 0.6× 2.7k 3.8× 154 8.1k
Raymond A. Pederson Canada 44 4.8k 1.8× 2.3k 0.9× 3.0k 2.4× 566 0.5× 2.5k 3.5× 125 6.9k
Grzegorz Godlewski United States 33 1.1k 0.4× 901 0.4× 874 0.7× 691 0.6× 770 1.1× 68 3.8k
Brendan Leighton United Kingdom 36 1.2k 0.5× 2.0k 0.8× 1.3k 1.0× 1.8k 1.5× 575 0.8× 96 4.3k
Susanne M. Clee Canada 32 1.0k 0.4× 1.6k 0.7× 2.2k 1.7× 756 0.6× 214 0.3× 54 4.1k
Juliette Janson Sweden 17 2.0k 0.8× 2.2k 0.9× 3.4k 2.7× 1.8k 1.5× 262 0.4× 23 5.9k

Countries citing papers authored by Kyle W. Sloop

Since Specialization
Citations

This map shows the geographic impact of Kyle W. Sloop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle W. Sloop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle W. Sloop more than expected).

Fields of papers citing papers by Kyle W. Sloop

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle W. Sloop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle W. Sloop. The network helps show where Kyle W. Sloop may publish in the future.

Co-authorship network of co-authors of Kyle W. Sloop

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle W. Sloop. A scholar is included among the top collaborators of Kyle W. Sloop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle W. Sloop. Kyle W. Sloop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gray, Sarah M., Kimberley El, Paul A. Grimsrud, et al.. (2025). α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion. Science Advances. 11(38). eady8048–eady8048.
2.
3.
Roell, William C., Tamer Coşkun, Teayoun Kim, et al.. (2024). Characterization of LY3324954 a long-acting glucagon-receptor agonist. Molecular Metabolism. 91. 102073–102073. 2 indexed citations
4.
Sangwung, Panjamaporn, et al.. (2024). Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease. American Journal of Physiology-Endocrinology and Metabolism. 327(5). E600–E615. 1 indexed citations
5.
El, Kimberley, Jonathan D. Douros, Francis S. Willard, et al.. (2023). The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature Metabolism. 5(6). 945–954. 74 indexed citations
6.
Collins, Kyla, Xinxin Yu, Brian A. Droz, et al.. (2023). GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice. Diabetes. 73(2). 292–305. 8 indexed citations
7.
8.
9.
Holter, Marlena M., Mridusmita Saikia, Elizabeth T. Anderson, et al.. (2022). 14-3-3-zeta mediates GLP-1 receptor agonist action to alter α cell proglucagon processing. Science Advances. 8(29). eabn3773–eabn3773. 10 indexed citations
10.
Willard, Francis S., Jonathan D. Douros, M Gabe, et al.. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 5(17). 314 indexed citations breakdown →
11.
Gray, Sarah M., Yurong Xin, Liz Ross, et al.. (2020). Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells. Journal of Biological Chemistry. 295(33). 11529–11541. 29 indexed citations
12.
West, Graham M., Francis S. Willard, Kyle W. Sloop, et al.. (2014). Glucagon-Like Peptide-1 Receptor Ligand Interactions: Structural Cross Talk between Ligands and the Extracellular Domain. PLoS ONE. 9(9). e105683–e105683. 11 indexed citations
13.
Prentice, Kacey J., Emma M. Allister, Ying Liu, et al.. (2014). The Furan Fatty Acid Metabolite CMPF Is Elevated in Diabetes and Induces β Cell Dysfunction. Cell Metabolism. 19(4). 653–666. 132 indexed citations
14.
Willard, Francis S., Denise Wootten, Aaron D. Showalter, et al.. (2012). Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin. Molecular Pharmacology. 82(6). 1066–1073. 44 indexed citations
15.
Wootten, Denise, Emilia E. Savage, Céline Valant, et al.. (2012). Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery. Molecular Pharmacology. 82(2). 281–290. 61 indexed citations
16.
Benson, Merrill D., Richard Smith, Gene Hung, et al.. (2010). Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid. 17(2). 43–49. 34 indexed citations
17.
Benson, Merrill D., Barbara Kluve‐Beckerman, Steven R. Zeldenrust, et al.. (2006). Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle & Nerve. 33(5). 609–618. 110 indexed citations
18.
19.
Smith, Timothy P. L., Aaron D. Showalter, Kyle W. Sloop, et al.. (2001). Identification of porcine Lhx3 and SF1 as candidate genes for QTL affecting growth and reproduction traits in swine. Animal Genetics. 32(6). 344–350. 13 indexed citations
20.
Slieker, Lawrence J., Kyle W. Sloop, & Peggy L. Surface. (1998). Differentiation Method-Dependent Expression of Leptin in Adipocyte Cell Lines. Biochemical and Biophysical Research Communications. 251(1). 225–229. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamer Coşkun Breakdown of academic impact, for papers by Lotte Bjerre Knudsen Breakdown of academic impact, for papers by Krister Bokvist Breakdown of academic impact, for papers by Bernard Portha Breakdown of academic impact, for papers by Christopher H.S. McIntosh Breakdown of academic impact, for papers by Raymond A. Pederson Breakdown of academic impact, for papers by Grzegorz Godlewski Breakdown of academic impact, for papers by Brendan Leighton Breakdown of academic impact, for papers by Susanne M. Clee Breakdown of academic impact, for papers by Juliette Janson
Rankless by CCL
2026